| |

Scientists Find New Way To Treat Mesothelioma

ByHolly Zink
Scientists Find New Way To Treat Mesothelioma

Scientists Find New Way To Treat Mesothelioma

Scientists think they can find new ways to treat mesothelioma by looking at its genetic makeup. The genetic changes and interactions between cancer cells and their environment could hold the key to new therapies.

This is the hope of a group of scientists from Italy who published their ideas in the International Journal of Molecular Sciences.

Mesothelioma Tumor and Cancer Genetics

Malignant pleural mesothelioma is a cancer caused by exposure to asbestos. One reason it is hard to treat is because it doesn’t have specific genetic targets like other types of cancer.

The area around the mesothelioma tumor also makes it hard to treat. The environment around the tumor affects how the tumor behaves and can cause it to spread to other parts of the body. In advanced cases, the cancer can invade nearby organs like the lungs and chest wall.

Scientists need to understand more about how the cancer genetics and how it interacts with its surroundings. This will help to find better ways to treat mesothelioma and help patients.

Genetic Factors Play a Role

Some studies have found that there could be genetic factors that affect the development of mesothelioma in people exposed to asbestos. The BRCA1-associated protein gene (BAP1) is one gene that could be associated with developing mesothelioma. Mutations or changes in this gene can make people more likely to develop mesothelioma after exposure to asbestos.

If scientists can identify genetic factors in people with symptoms of mesothelioma, they could reach a diagnosis more quickly. They could also figure out what type of mesothelioma a person has, which would help doctors to pick the most effective therapies for treatment.

One area of interest is how low oxygen levels affect the cancer cells and their genes. This is called hypoxia. Hypoxia can help cancer cells to grow and spread by changing how the mesothelioma genes are expressed.

Scientists are also looking at specific molecules called transcripts and miRNA. Molecules called microvesicles and exosomes may be involved in the development and growth of the cancer.

These molecules are important in understanding the disease. They may also offer potential targets for new therapies that could be developed for clinical use in the future.

Source

Stella GM, Marchiò C, Bari E, et al. The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints. Int J Mol Sci. 2023;24(4):3496. Published 2023 Feb 9. doi:10.3390/ijms24043496. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963101/#B66-ijms-24-03496

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…